The relationship between psychologic distress and cancer-related fatigue

Cancer

Volumn 98, Issue 1, 2003, Pages 198-203

  Tchekmedyian, N Simon ^a   Kallich, Joel ^b   McDermott, Anne ^c   Fayers, Peter ^d   Erder, M Haim ^b  

^a Pacific Shores Medical Group   (United States)

^b AMGEN INC   (United States)

^c Health Economics and Outcomes Research   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anemia; Anxiety; Depression; Fatigue; Lung neoplasms; Quality of life

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ANXIETY; ARTICLE; CANCER; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISTRESS SYNDROME; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANXIETY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 0038339680     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11463     Document Type: Article

References (17)

1. Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751-757.
2. Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10:19-28.
3. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer. 1993;29A(Suppl 1):S51-S58.
4. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist. 1999;4:1-10.
5. Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity, and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000;11:561-567.
6. Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract. 2000;14:275-298.
7. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18:893-903.
8. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized Phase III trial of darbepo-etin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
9. Derogatis LR. Brief Symptom Inventory administration, scoring, and procedures manual. Minneapolis: NCS Pearson, Inc., 1993.
10. Kornblith AB, Herdon JE II, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Ann Oncol. 1998;9:297-306.
11. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34:13-19.
12. Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) scales, version 4. Evanston, IL: Center on Outcomes Research and Education, Evanston Northwestern Healthcare and Northwestern University, 1997.
13. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528-538.
14. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
15. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
16. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
17. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.